Management of Cirrhosis and Hyperbilirubinemia

Diagnosis and Assessment

The European Association for the Study of the Liver (EASL) characterizes acute-on-chronic liver failure (ACLF) by acute onset with rapid deterioration, liver failure (elevated bilirubin and INR), and at least one extrahepatic organ failure 1
Assessment for infection should include complete blood count, comprehensive metabolic panel, coagulation studies, inflammatory markers (CRP, WBC count), blood cultures, paracentesis, and abdominal imaging to evaluate for biliary obstruction or hepatocellular carcinoma 1

The American Association for the Study of Liver Diseases (AASLD) recommends empiric antibiotics, such as ceftriaxone (1 g/24h), should be started immediately if infection is suspected, particularly in patients with nosocomial infections or decompensated cirrhosis 2
Intravenous albumin (1.5 g/kg at diagnosis, followed by 1 g/kg on day three) should be administered to patients with baseline serum bilirubin ≥4 mg/dl or serum creatinine ≥1 mg/dl to reduce the incidence of hepatorenal syndrome and mortality 2
The International Club of Ascites recommends avoiding nephrotoxic medications, such as aminoglycosides and NSAIDs, and large volume paracentesis during acute deterioration 2

Patients with bilirubin >6 mg/dL should be referred for transplant evaluation, as hyperbilirubinemia is a strong predictor of poor outcomes in cirrhosis 3
A MELD score >12 warrants transplant evaluation, according to the United Network for Organ Sharing (UNOS) 3

If variceal bleeding is present, vasoactive drugs (terlipressin, somatostatin, or octreotide) should be initiated, and endoscopic therapy should be performed within 12 hours, with consideration of early TIPS placement in high-risk patients 2